Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


J&J/Omrix’s Evicel Wins CHMP Recommendation

This article was originally published in The Pink Sheet Daily

Executive Summary

Human fibrogen/thrombin product would be indicated for supportive treatment in surgery.

You may also be interested in...

ZymoGenetics Will Ship Topical Hemostat Recothrom In Two Weeks

Company will price the recombinant, plasma-free thrombin at a 20 percent premium over competitor King's bovine-derived Thrombin JMI.

Johnson & Johnson/Omrix Win General Surgery Hemostasis Approval For Evicel

Approval puts Evicel marginally ahead of ZymoGenetics’ recombinant human fibrin sealant rhThrombin, which has a Jan. 17 action date.

Hologic's Adiana Permanent Birth Control Device Takes On Conceptus' Essure

Adiana uses a polymer matrix insert to block the fallopian tubes instead of a metal coil, offering a benefit over Essure, which carries a perforation risk on implantation, Hologic exec says.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts